FrancophonIA/ELRC3.0 huggingface dataset:
English: • abnormal blood test results (decrease in magnesium and potassium, too much citrate, or increase in white blood cells)
Maltese: • riżultati ta' testijiet tad-demm anormali (tnaqqis fil-magnesium u l-potassium, wisq ċitrat, jew żieda fiċ-ċelluli bojod tad-demm)
English: Exploratory analyses were performed to confirm resolution of dyserythropoiesis, the fundamental physiologic characteristic of TDT, in the bone marrow.
Maltese: Twettqu analiżijiet esploratorji biex jikkonfermaw ir-riżoluzzjoni ta' diseritropoeżi, il-karatteristika fiżjoloġika fundamentali ta' TDT, fil-mudullun.
English: Vomiting, Lip swelling, Abdominal pain, Abdominal pain upper, Paraesthesia oral
Maltese: OĦRA, JEKK MEĦTIEĠA ŻOMM DAN ID-DOKUMENT U PPREPARA BIEX IKUN DISPONIBBLI
English: HSC transplantation must be appropriate for a patient with TDT to be treated with Zynteglo (see section 4.4).
Maltese: Trapjant ta' HSC irid ikun xieraq għal pazjent b'TDT li jkun ikkurat b'Zynteglo (ara sezzjoni 4.4).
English: Eighteen adults and adolescents with TDT with a non-β0/β0 genotype have been treated with Zynteglo in Phase 3 studies (N=15, HGB-207; N=3, HGB-212) and their median (min, max) duration of follow-up was 10.0 (1.3, 22.2) months.
Maltese: Tmintax-il adult u adolexxent b'TDT b'ġenotip mhux β0/β0 ġew ikkurati b'Zynteglo fi studji ta' Fażi 3 (N=15, HGB-207; N=3, HGB-212) u t-tul medjan (min, mass) tagħhom tas-segwitu kien 10.0
English: BATCH NUMBER, DONATION AND PRODUCT CODES
Maltese: NUMRU TAL-LOTT, DONAZZJONI U KOWDS TAL-PRODOTT
English: Agitation
Maltese: mobilizzazzjoni
English: Delayed platelet engraftment
Maltese: DOŻA TAL-PRODOTT MEDIĊINALI
English: Package leaflet: Information for the patient or carer Zynteglo 1.2-20 × 106 cells/mL dispersion for infusion
Maltese: Informazzjoni għall-pazjent jew għall-persuna li tieħu ħsieb il-pazjent Zynteglo 1.2-20 × 106 ċelluli/mL dispersjoni għall-infużjoni
English: • hiccups
Maltese: • sulluzzu
English: Administer each infusion bag via intravenous infusion over a period of less than 30 minutes.
Maltese: Kull borża tal-infużjoni għandha tingħata f'inqas minn 30 minuta.
English: • transfusion reaction
Maltese: • reazzjoni ta' trasfużjoni
English: Busulfan dose adjustments were made as needed based on pharmacokinetic monitoring.
Maltese: Aġġustamenti fid-doża ta' busulfan saru skont il-bżonn abbażi ta' monitoraġġ farmakokinetiku.
English: Figure 1 Median total haemoglobin over time in non-β0/β0 TDT patients treated with Zynteglo who have achieved transfusion independence (Studies HGB-204,
Maltese: Figura 1 L-emoglobina medjana totali matul iż-żmien f'pazjenti b'TDT mhux β0/β0 ikkurati b'Zynteglo li kisbu indipendenza tat-trasfużjoni (Studji
English: Italia bluebird bio (Italy) S.r.l.
Maltese: Nederland bluebird bio (Netherlands) BV Tel:
English: 3521AZ Utrecht The Netherlands medinfo@bluebirdbio.com
Maltese: L-Olanda medinfo@bluebirdbio.com
English: After carefully removing the outer metal container, thaw each infusion bag at 37°C in a water bath or dry bath for approximately 2-4 minutes.
Maltese: Wara li tneħħi bir-reqqa l-kontenitur tal-metall ta' barra, ħoll kull borża tal-infużjoni f'temperatura ta' 37°C f'banju tal-ilma jew banju xott għal madwar 2-4 minuti.
English: A patient may have multiple infusion bags.
Maltese: Pazjent jista' jkollu boroż tal-infużjoni multipli.
English: ANNEX III LABELLING AND PACKAGE LEAFLET
Maltese: Tabella 2 Reazzjonijiet avversi attribwiti għal kondizzjonament majeloablattiv
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Zynteglo in one or more subsets of the paediatric population in β-thalassaemia (see section 4.2 for information on paediatric use).
Maltese: Prodott mediċinali li jingћata b'riċetta speċjali u ristretta tat-tabib (ara Anness I: Sommarju talKaratteristiċi tal-Prodott, sezzjoni 4.2).
English: Mucosal inflammation, Face oedema, Hypothermia, Feeling cold, Pain, Xerosis
Maltese: Dispepsja, Disfaġija, Esofaġite, Emorrojdi, Proktalġija, Xufftejn xotti
English: Zynteglo is intended for autologous use (see section 4.4) and should only be administered once.
Maltese: Zynteglo huwa maħsub għal użu awtologu (ara sezzjoni 4.4) u għandu jingħata darba biss.
English: For 8 patients who had sufficient on-study follow-up to obtain a 12-month follow-up bone marrow assessment, myeloid/erythroid ratios for 7 patients increased from a range of 0.1 to 0.5 at baseline to a range of 0.6 to 1.9 approximately 12 months after Zynteglo infusion, suggesting that Zynteglo improves erythropoiesis in patients with TDT.
Maltese: Għal 8 pazjenti li kellhom segwitu fuq l-istudju suffiċjenti biex jiksbu valutazzjoni ta' segwitu ta' 12-il xahar tal-mudullun, il-proporzjonijiet tal-majelojde/eritrojdju għal 7 pazjenti żdiedu minn medda ta' 0.1 sa 0.5 fil-linja bażi għal medda ta' 0.6 sa 1.9 madwar 12-il xahar wara l-infużjoni ta' Zynteglo, li tissuġġerixxi li Zynteglo jtejjeb leritropoeżi f'pazjenti b'TDT.
English: Other medicines and Zynteglo
Maltese: Kif taħżen Zynteglo
English: After Zynteglo infusion patient iron chelation was managed at physician discretion.
Maltese: Dan il-prodott mediċinali fih ċelluli modifikati ġenetikament.
English: Store in the vapour phase of liquid nitrogen at ≤-140°C until ready for thaw and administration.
Maltese: Aħżen fil-fażi tal-fwar tan-nitroġenu likwidu f'temperatura ta' ≤-140°C sakemm tkun lesta biex tinħall u tingħata.
English: Lip dry
Maltese: TAGĦRIF
English: MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
Maltese: TAS-SUSTANZA/I BIJOLOĠIKA(ĊI) ATTIVA/I
English: Veno-occlusive liver disease, Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood bilirubin increased
Maltese: Disturbi fil-fwied u fil-marrara Marda veno‑okklussiva tal fwied, Żieda fl-alanine aminotransferase, Żieda flaspartate aminotransferase,
English: • stomach pain, upset stomach, constipation, diarrhoea
Maltese: • uġigħ fl-istonku, stonku mqalleb, stitikezza, dijarea
English: Some side effects observed in clinical studies with Zynteglo are related to mobilisation and blood stem cell collection or to the chemotherapy medicine used to prepare your bone marrow for treatment with Zynteglo.
Maltese: Xi effetti sekondarji osservati fi studji kliniċi b'Zynteglo huma relatati mal-mobilizzazzjoni u l-ġbir taċ-ċelluli staminali tad-demm jew mal-mediċina kimoterapewtika użata biex tipprepara l-mudullun tiegħek għal kura b'Zynteglo.
English: A pharmacology, biodistribution, toxicity and genotoxicity study was conducted in a mouse model of β-thalassaemia.
Maltese: Studju dwar il-farmakoloġija, il-bijodistribuzzjoni, it-tossiċità u l-ġenotossiċità sar f'mudell tal-ġrieden ta' β-talassemija.
English: Do not use this medicine after the expiry date which is stated on the outer container label(s) and infusion bag label(s).
Maltese: Tużax din il-mediċina wara d-data ta' meta tiskadi li tidher fuq it-tikketta(i) tal-kontenitur ta' barra u t-tikketta(i) tal-borża tal-infużjoni.
English: For most patients, the minimum number of CD34+ cells to manufacture Zynteglo was collected with 1 cycle of mobilisation and apheresis.
Maltese: Għal ħafna mill-pazjenti, in-numru minimu ta' ċelluli CD34+ biex jimmanifatturaw Zynteglo nġabar b'ċiklu wieħed ta' mobilizzazzjoni u afereżi.
English: Zynteglo is used to treat a serious genetic disease called transfusion-dependent beta-thalassaemia (TDT), which includes the disease commonly known as beta-thalassaemia major, in people 12 years and older.
Maltese: Zynteglo jintuża biex jikkura marda ġenetika serja msejħa beta-talassemija dipendenti fuq it-trasfużjoni (TDT), li tinkludi l-marda normalment magħrufa bħala talassemija beta maġġuri, f'nies li għandhom 12-il sena u aktar.
English: The full EPAR for Caprelsa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The active substance in Caprelsa, vandetanib, is a ‘protein tyrosine kinase inhibitor'.
Maltese: Is-sustanza attiva f'Caprelsa, il-vandetanib, hija ‘inibitur tat-tirożina kinażi tal-proteina'.
English: Caprelsa contains the active substance vandetanib.
Maltese: Caprelsa fih is-sustanza attiva vandetanib.
English: Other information about Caprelsa
Maltese: Informazzjoni oħra dwar Caprelsa
English: This is a summary of the European public assessment report (EPAR) for Caprelsa.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Caprelsa.
English: Of the 16 children treated with Caprelsa, 7 (44%) had partial response on the ORR scale, which was comparable to the response rate in adults.
Maltese: Mis-16-il tifel u tifla kkurati b'Caprelsa, 7 (44%) kellhom rispons parzjali fuq l-iskala ORR, li kienet komparabbli mar-rata ta' rispons fl-adulti.
English: Caprelsa is available as tablets (100 mg and 300 mg) and the recommended dose for adults is 300 mg once a day, taken at around the same time each day.
Maltese: Caprelsa jiġi bħala pilloli (100 mg u 300 mg) u d-doża rakkomandata għall-adulti hija 300 mg darba kuljum, li tittieħed kuljum fl-istess ħin.
English: It must not be used in people with a problem called ‘congenital long QTc syndrome' or who have a QTc interval longer than 480 milliseconds.
Maltese: Ma għandux jintuża f'pazjenti bi problema msejħa ‘sindrome QTc twil konġenitali' jew li għandhom intervall QTc itwal minn 480 millisekonda.
English: Why is Caprelsa approved?
Maltese: Għaliex ġie approvat Caprelsa?
English: In a second main study, Caprelsa was given to children aged between 9 and 17 years with hereditary medullary thyroid cancer.
Maltese: Fi studju ewlieni ieħor, Caprelsa ngħata lil tfal li għandhom bejn 9 u 17-il sena bil-kanċer tat-tirojde medullari ereditarju.
English: Caprelsa can affect the electrical activity of the heart including a measurement called QTc interval.
Maltese: Caprelsa jista' jaffettwa l-attivita ellettrika tal-qalb inkluż kejl imsejjaħ intervall QTc.
English: Caprelsa vandetanib
Maltese: Sommarju tal-EPAR għall-pubbliku vandetanib
English: The company that markets Caprelsa will ensure that doctors who are expected to prescribe Caprelsa receive educational material containing important safety information about Caprelsa, including measures to manage the risk of QTc prolongation and other potential side effects, and a patient alert card and guidance for children or their carers.
Maltese: Il-kumpanija li tqiegħed Caprelsa fis-suq sejra tiżgura li t-tobba li huma mistennija li jippreskrivu Caprelsa jirċievu materjal edukattiv li fih informazzjoni importanti dwar is-sigurtà dwar Caprelsa, inklużi miżuri ta' ġestjoni tar-riskju ta' prolungament tal-QTc u effetti sekondarji potenzjali oħrajn, u kard ta' twissija tal-pazjent u gwida għat-tfal u għal dawk li jieħdu ħsiebhom.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Caprelsa on 17 February 2012.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Caprelsa fis-17 ta' Frar 2012.
English: The most commonly reported side effects with Caprelsa are diarrhoea, rash, nausea (feeling sick), high blood pressure and headache.
Maltese: L-effetti sekondarji l-aktar komuni rrapportati b'Caprelsa huma dijarrea, raxx, nawżja (tħossok ma tiflaħx), pressjoni tad-demm għolja u wġigħ ta' ras.
English: What are the risks associated with Caprelsa?
Maltese: X'inhuma r-riskji assoċjati ma' Caprelsa?
English: Caprelsa has been given ‘conditional approval'.
Maltese: Caprelsa ingħata ‘approvazzjoni b'kondizzjoni'.
English: Caprelsa is a cancer medicine that is used in adults and children above 5 years of age to treat medullary thyroid cancer, a cancer that starts off in the cells in the thyroid gland that produce the hormone calcitonin.
Maltese: Caprelsa hija mediċina kontra l-kanċer li tintuża f'adulti u tfal li għandhom aktar minn 5 snin biex tikkura kanċer tat-tirojde medullari, kanċer li jibda fiċ-ċelluli tal-glandola tat-tirojde li jipproduċu lormon calcitonin.
English: The main measure of effectiveness was ‘overall response rate' (ORR) which considers several features of the disease.
Maltese: Il-kejl ewlieni tal-effikaċja kien 'ir-rata ta' rispons globali' (ORR) li tikkunsidra diversi fatturi tal-marda.
English: This means that it blocks the activity of enzymes known as tyrosine kinases.
Maltese: Dan ifisser li timblokka l-attività ta' enzimi magħrufin bħala tirożina kinażi.
English: What information is still awaited for Caprelsa?
Maltese: Liema informazzjoni għadha mistennija għal Caprelsa?
English: The medicine can only be obtained with a prescription and treatment with Caprelsa should be started and supervised by a doctor who has experience of treating medullary thyroid cancer, of using cancer medicines and of assessing electrocardiograms (ECG, a test that measures the electrical activity of the heart).
Maltese: Il-mediċina tista' tinkiseb biss b'riċetta tat-tabib u l-kura b'Caprelsa għandha tinbeda u tiġi sorveljata minn tabib li jkollu esperjenza fil-kura ta' kanċer tat-tirojde medullari, permezz ta' mediċini kontra lkanċer u valutazzjoni ta' elettrokardjogrammi (ECG, test li jkejjel l-attività elettrika tal-qalb).
English: Patients who cannot swallow tablets can mix the tablet in plain (non-sparkling) water.
Maltese: Pazjenti li ma jistgħux jibilgħu pilloli jistgħu jħalltu l-pillola fl-ilma (mhux fexfiexi).
English: The doctor may temporarily stop Caprelsa treatment and reduce the dose if the patient has abnormal ECG or severe side effects.
Maltese: It-tabib jista' jwaqqaf il-kura b'Caprelsa għal żmien temporanju u jnaqqas id-doża jekk il-pazjent ikollu effetti sekondarji severi jew ECG anormali.
English: This means that there is more evidence to come about the medicine, in particular on the size of the benefit in patients without the RET mutation.
Maltese: Dan ifisser li għad hemm aktar evidenza x'tingħata dwar il-mediċina, b'mod partikolari dwar id-daqs tal-benefiċċju f'pazjenti mingħajr il-mutazzjoni RET.
English: Vandetanib also blocks the activity of RET receptors, which play a role in the growth of medullary thyroid cancer cells.
Maltese: Vandetanib jimblokka wkoll l-attività tar-riċetturi RET, li għandhom rwol fit-tkabbir ta' ċelloli tal-kanċer tat-tirojde medullari.
English: Patients must be given a patient alert card containing important safety information and they must be informed by their doctor about the risks of Caprelsa.
Maltese: Dan mhux intiż biex jipprovdi konsultazzjoni prattika dwar l-użu ta' Caprelsa.
English: The Committee noted the potential risk for QTc interval prolongation, and measures were introduced to minimise this risk.
Maltese: Il-Kumitat innota r-riskju potenzjali għal titwil tal-intervall QTc, u ġew introdotti miżuri sabiex jitnaqqas dan ir-riskju.
English: The CHMP concluded that the benefits of Caprelsa outweigh its risks in patients whose disease is spreading quickly and is causing symptoms, since they are in urgent need of treatment.
Maltese: IsCHMP ikkonkluda li l-benefiċċji ta' Caprelsa huma akbar mir-riskji tiegħu f'pazjenti li l-marda tagħhom hija kemm aggressiva kif ukoll tikkawża sintomi, minħabba li huma fi ħtieġa urġenti ta' kura.
English: By blocking the activity of VEGF receptors, the medicine reduces the blood supply to the cancer cells, slowing down the cancer's growth.
Maltese: Billi timblokka l-attività ta' riċetturi VEGF, il-mediċina tnaqqas il-provvista tad-demm liċ-ċelloli tal-kanċer, u tnaqqas it-tkabbir tal-kanċer.
English: In a main study, Caprelsa was more effective than placebo (a dummy treatment) in adults with medullary thyroid cancer that could not be removed by surgery or had spread to other parts of the body.
Maltese: Fi studju ewlieni, Caprelsa kien aktar effettiv minn plaċebo (kura finta) f'adulti b'kanċer tat-tirojde medullari li ma jistax jitneħħa b'kirurġija jew li nfirex għal partijiet oħra tal-ġisem.
English: On average, patients taking Caprelsa lived for 30.5 months without their disease getting worse, compared with 19.3 months for patients taking placebo.
Maltese: Bħala medja, il-pazjenti li ħadu Caprelsa għexu għal 30.5 xhur mingħajr ma l-marda tagħhom marret għall-agħar, meta mqabbel ma' 19.3 xhur għal pazjenti li ħadu plaċebo.
English: Date of last renewal: 6 November 2007
Maltese: Data ta' l-aħħar tiġdid: 6 ta' Novembru 2007
English: PACKAGE SIZE 250 ml
Maltese: 250 ml
English: Phenothiazines and alpha-2-agonists:
Maltese: Phenothiazines u alpha-2-agonists:
English: Overdose (symptoms, emergency procedures, antidotes):
Maltese: Doża excesiva (sintomi, proċeduri ta' emerġenza, antidoti):
English: Inspired concentration:
Maltese: Konċentrazzjoni inspirata:
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 11 December 2002
Maltese: DATA TA' L-EWWEL AWTORIZZAZZJONI / TIĠDID TA' L-AWTORIZZAZZJONI Data ta' l-ewwel awtorizzazzjoni: 11 ta' Dicembru 2002
English: MARKETING AUTHORISATION NUMBER(S) EU/2/02/035/007
Maltese: NUMRU TA' AWTORIZZAZZJONI TAL-KUMMERĊ EU/2/02/035/007
English: Benzodiazepines and opioids:
Maltese: Benzodijażepini u opijojdi:
English: 1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C4H2F6O), also known as Compound A, is produced when sevoflurane interacts with soda lime or barium hydroxide.
Maltese: 1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C4H2F6O), magħruf ukoll bħala Kompost A, jiġi ffurmat meta sevoflurane jitħallat ma soda lime jew barium hydroxide.
English: STATEMENT OF ACTIVE SUBSTANCES 100% sevoflurane
Maltese: DIKJARAZZJONI TAS-SUSTANZA ATTIVA 100% sevoflurane
English: Anticholinergics:
Maltese: Antikolinerġiċi:
English: Active substance: Each bottle contains 250 ml sevoflurane (100%).
Maltese: Kull flixkun fih 250 ml sevoflurane (100%).
English: The Minimum Alveolar Concentration (MAC) of sevoflurane in dogs is 2.36% and the MAC in cats 3.1%.
Maltese: Minima (MAC) ta' sevoflurane għal klieb hi 2.36% u l-MAC fil-qtates hi ta' 3.1%.
English: In the cat surgical anaesthesia is maintained with sevoflurane concentrations of 3.7-4.5%.
Maltese: Fil-qattus l'anesteżija kirurġika tinżamm b'konċentrazzjonijiet ta' 3.7-4.5% sevoflurane.
English: The principle metabolites are hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO2.
Maltese: Il-metaboliti prinċipali huma hexafluoroisopropanol (HFIP) bl-eliminazzjoni ta' florid inorganiku u CO2.
English: The half-life for the slow elimination phase is approximately 50 minutes.
Maltese: Il-halflife ta' l-eliminazzjoni tal-fażi bil-mod hi ta' madwar 50 minuta.
English: In dogs exposed to 4% sevoflurane for 3 hours, mean peak maximum serum fluoride concentrations of 20.0 ± 4.8 µmol/l have been observed after 3 hours of anaesthesia.
Maltese: Fi klieb esposti għal 3 sigħat b'4% sevoflurane, ġiet osservata medja ta' konċentrazzjonijiet massimi ta' florid fis-sirum ta' 20.0 ± 4.8 µmol/l wara 3 sigħat t'anesteżija.
English: A minimal amount of sevoflurane is required to be dissolved in the blood before the alveolar partial pressure is in equilibrium with the arterial partial pressure because of the low solubility of sevoflurane in blood (blood/gas partition coefficient at 30°C is 0.63 to 0.69).
Maltese: Ammont minimu ta' sevoflurane fid-demm hu meħtieġ biex il-pressjoni parzjali alveolari tkun f'ekwilibriju mal-pressjoni parzjali arterjali minħabba s-solubilità baxxa ta' sevoflurane fid-demm (koeffiċjenza diviżorja demm/gas f'temperatura ta' 30°C hi bejn 0.63 u 0.69).
English: For mask induction using sevoflurane, inspired concentrations of 5 to 7% sevoflurane with oxygen are employed to induce surgical anaesthesia in the healthy dog, and 6 to 8% sevoflurane with oxygen in the cat.
Maltese: L-użu ta' maskra għal induzzjoni minn sevoflurane, f'konċentrazzjoni ispirata ta' 5 sa 7% sevoflurane bl-ossiġnu għandu jingħata biex jinbeda l-illuppjar kirurġiku fuq kelb f'saħħtu u 6 sa 8% sevoflurane bl-ossiġnu fil-qattus.
English: Excipient(s) For the full list of excipients, see section 6.1.
Maltese: Għal-lista sħiħa tal-ingredjenti (mhux attivi), ara s-sezzjoni 6.1.
English: sevoflurane
Maltese: IEĦOR
English: No other metabolic pathways for sevoflurane have been identified.
Maltese: Għadhom ma ġewx identifikati rotot metaboliċi oħra għas-sevoflurane.
English: Sevoflurane is metabolised to a limited extent in the dog (1 to 5%).
Maltese: Sevoflurane huwa metaboliżżat b'mod ristrett fil-klieb (1 sa 5%).
English: Multiples of MAC are used as a guide for surgical levels of anaesthesia, which are typically 1.3 to 1.5 times the MAC value.
Maltese: Multiplikazzjonijiet tal-MAC jintużaw bħala gwida għal livelli kirurġiċi ta' loppju, li tipikament huma minn 1.3 sa 1.5 drabi tal-valur tal-MAC.
English: Use only according to the risk/benefit assessment of the responsible veterinarian.
Maltese: Uża biss b'konformità ma' l-analiżi dwar ir-riskju/siwi talveterinarju responsabbli.
English: Sevoflurane is compatible with phenothiazines and alpha-2-agonists commonly used in veterinary practice.
Maltese: Sevoflurane huwa kompattibli ma' phenothiazines u alfa-2-agonisti użati ta' spiss fil-prattika veterinarja.
English: Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents or other appropriate techniques.
Maltese: Dipressjoni karjovaskulari għandha tiġi ttrattata bi plasma expanders, b'agenti li jistimulaw il-pressjoni, aġenti kontra l-arritmiji u teknikalitajiet oħra xierqa.
English: Parent compound (the dominant fraction) is eliminated via the lungs.
Maltese: Is-sustanza oriġinali (il-parti dominanti) hija eliminata mill-pulmun.
English: Limited data are available on the effects of the highly potent alpha-2agonists (medetomidine, romifidine and dexmedetomidine) as premedication.
Maltese: Hemm informazzjoni ristretta disponibbli fuq l-effetti qawwija talagonisti alpha-2, (medetomidine, romifidine u dexmedetomidine) bħala trattament mediku ta' qabel.
English: Hypotension, tachypnoea, muscle tenseness, excitation, apnoea, muscle fasciculations and emesis have been reported as very common adverse reactions, based on post-authorisation spontaneous reporting experience.
Maltese: Pressjoni baxxa, nifs mgħaġġel, tensjoni fil-muskoli, eċċitament, qtugħ ta' nifs, faxxikli fil-muskoli, u remettar ġew rappurtati bħala effetti mhux mixtieqa komuni ħafna, ibbażati fuq l-esperjenza ta' rapport spontanji wara l-awtorizzazzjoni.
English: Anaesthetic regimens that include opioid, alpha-2-agonist, benzodiazepine or phenothiazine premedication will allow the use of lower sevoflurane maintenance concentrations.
Maltese: Reġimi anestetiċi li jinkludi pre-medikazzjoni bl-opijojdi, alpha-2agonist, benzodijażepini jew phenothiazine jippermettu l-użu ta' konċentrazzjonijiet aktar baxxi ta' sevoflurane sabiex tinżamm anesteżija.
English: There are limited data to support the safety of sevoflurane in animals less than 12 weeks of age.
Maltese: Id-data dwar is-sigurtà ta' sevoflurane f'annimali ta' età anqas minn 12-il ġimgħa hija limitata.
English: Sevoflurane in the cat did not increase intracranial pressure during normocapnia.
Maltese: Fil-qattus sevoflurane ma żiedx ilpressjoni intrakranjali waqt normocapnia.
English: INDICATION(S) For induction and maintenance of anaesthesia.
Maltese: INDIKAZZJONI(JIET) Għal induzzjoni u manteniment ta' anesteżija
English: It may be reversed by administration of anticholinergics.
Maltese: Jista' jittreġġa lura bl-amministrazzjoni ta' antikolinerġiċi.
English: • Avoid using masking procedures for prolonged induction and maintenance of general anaesthesia.
Maltese: • Evita li tuża maskri għal induzzjoni fit-tul u żamma ta' anesteżija ġenerali.
English: During sevoflurane induction, there is a rapid increase in alveolar concentration towards the inspired concentration, with the ratio of inspired to end-tidal concentration of sevoflurane reaching a value of 1 within 10 minutes.
Maltese: Waqt l-induzzjoni b'sevoflurane, hemm żieda ta' malajr fil-konċentrazzjoni alveolari li twassal lejn il-konċentrazzjoni inspirata, bil-proporzjon ta' konċentrazzjoni ispiratorja għal dik ta' l-imbatt ta'sevoflurane tkun ta' 1 fi żmien 10 minuti.